Table 3 Open in new tab Prognostic...

	Renal cancer crude HR (95% c.i.)	Lung cancer crude HR (95% c.i.)	Colorectal cancer crude HR (95% c.i.)	Other cancer crude HR (95% c.i.)
Sex
Female	1.28 (0.88–1.85)	0.95 (0.62–1.46)	0.92 (0.40–2.14)	0.77 (0.42–1.40)
Male	1.00	1.00	1.00	1.00
Age (per 10 years)	1.16 (0.96–1.40)	0.73 (0.55–0.98)	1.52 (0.95–2.41)	1.05 (0.78–1.42)
Age at surgery
Under 60 years	1.00	1.00	1.00	1.00
60–70 years	1.10 (0.71–1.72)	0.66 (0.41–1.07)	1.45 (0.48–4.32)	0.72 (0.36–1.43)
More than 70 years	1.26 (0.79–2.01)	0.50 (0.27–0.93)	3.16 (1.07–9.30)	1.55 (0.78–3.08)
CCI (per 1)	1.12 (0.98–1.28)	1.25 (0.99–1.59)	1.19 (0.80–1.77)	1.29 (0.92–1.80)
BMI in kg/m² (per 1)	0.97 (0.93–1.02)	0.99 (0.95–1.04)	1.07 (0.97–1.17)	0.97 (0.90–1.03)
Tumour size
Under 25 mm	1.00	1.00	1.00	1.00
25–50 mm	1.00 (0.62–1.60)	1.32 (0.72–2.42)	1.54 (0.55–4.34)	0.75 (0.33–1.71)
More than 50 mm	1.58 (0.91–2.72)	2.66 (1.44–4.89)	2.16 (0.76–6.16)	1.12 (0.49–2.57)
Size (per 10 mm)	1.04 (0.97–1.13)	1.08 (1.02–1.15)	1.05 (0.94–1.17)	1.03 (0.95–1.10)
Mode of discovery
Synchronous	2.17 (1.47–3.20)	1.33 (0.84–2.10)	0.98 (0.37–2.58)	3.83 (1.53–9.55)
Metachronous	1.00	1.00	1.00	1.00
Extra-adrenal metastases at time of surgery
No	1.00	1.00	1.00	1.00
Yes	1.21 (0.81–1.83)	1.79 (1.07–3.01)	1.41 (0.66–3.00)	1.71 (0.96–3.04)
Surgical approach
Laparoscopic	1.00	1.00	1.00	1.00
Open	2.07 (1.38–3.09)	1.27 (0.69–2.36)	1.11 (0.53–2.31)	2.00 (1.12–3.58)
Radicality
R0 resection	1.00	1.00	1.00	1.00
R1 resection	1.79 (1.24–2.60)	2.35 (1.51–3.65)	1.90 (0.92–3.90)	0.83 (0.46–1.50)
R2 resection	3.02 (0.93–9.74)	2.47 (0.98–6.25)	4.58 (0.99–21.17)	3.60 (1.07–12.10)

Renal cancer crude HR (95% c.i.)

Lung cancer crude HR (95% c.i.)

Colorectal cancer crude HR (95% c.i.)

Other cancer crude HR (95% c.i.)

Sex

Female

1.28 (0.88–1.85)

0.95 (0.62–1.46)

0.92 (0.40–2.14)

0.77 (0.42–1.40)

Male

1.00

Age (per 10 years)

1.16 (0.96–1.40)

0.73 (0.55–0.98)

1.52 (0.95–2.41)

1.05 (0.78–1.42)

Age at surgery

Under 60 years

1.00

60–70 years

1.10 (0.71–1.72)

0.66 (0.41–1.07)

1.45 (0.48–4.32)

0.72 (0.36–1.43)

More than 70 years

1.26 (0.79–2.01)

0.50 (0.27–0.93)

3.16 (1.07–9.30)

1.55 (0.78–3.08)

CCI (per 1)

1.12 (0.98–1.28)

1.25 (0.99–1.59)

1.19 (0.80–1.77)

1.29 (0.92–1.80)

BMI in kg/m² (per 1)

0.97 (0.93–1.02)

0.99 (0.95–1.04)

1.07 (0.97–1.17)

0.97 (0.90–1.03)

Tumour size

Under 25 mm

1.00

25–50 mm

1.00 (0.62–1.60)

1.32 (0.72–2.42)

1.54 (0.55–4.34)

0.75 (0.33–1.71)

More than 50 mm

1.58 (0.91–2.72)

2.66 (1.44–4.89)

2.16 (0.76–6.16)

1.12 (0.49–2.57)

Size (per 10 mm)

1.04 (0.97–1.13)

1.08 (1.02–1.15)

1.05 (0.94–1.17)

1.03 (0.95–1.10)

Mode of discovery

Synchronous

2.17 (1.47–3.20)

1.33 (0.84–2.10)

0.98 (0.37–2.58)

3.83 (1.53–9.55)

Metachronous

1.00

Extra-adrenal metastases at time of surgery

1.00

Yes

1.21 (0.81–1.83)

1.79 (1.07–3.01)

1.41 (0.66–3.00)

1.71 (0.96–3.04)

Surgical approach

Laparoscopic

1.00

Open

2.07 (1.38–3.09)

1.27 (0.69–2.36)

1.11 (0.53–2.31)

2.00 (1.12–3.58)

Radicality

R0 resection

1.00

R1 resection

1.79 (1.24–2.60)

2.35 (1.51–3.65)

1.90 (0.92–3.90)

0.83 (0.46–1.50)

R2 resection

3.02 (0.93–9.74)

2.47 (0.98–6.25)

4.58 (0.99–21.17)

3.60 (1.07–12.10)

	Renal cancer crude HR (95% c.i.)	Lung cancer crude HR (95% c.i.)	Colorectal cancer crude HR (95% c.i.)	Other cancer crude HR (95% c.i.)
Sex
Female	1.28 (0.88–1.85)	0.95 (0.62–1.46)	0.92 (0.40–2.14)	0.77 (0.42–1.40)
Male	1.00	1.00	1.00	1.00
Age (per 10 years)	1.16 (0.96–1.40)	0.73 (0.55–0.98)	1.52 (0.95–2.41)	1.05 (0.78–1.42)
Age at surgery
Under 60 years	1.00	1.00	1.00	1.00
60–70 years	1.10 (0.71–1.72)	0.66 (0.41–1.07)	1.45 (0.48–4.32)	0.72 (0.36–1.43)
More than 70 years	1.26 (0.79–2.01)	0.50 (0.27–0.93)	3.16 (1.07–9.30)	1.55 (0.78–3.08)
CCI (per 1)	1.12 (0.98–1.28)	1.25 (0.99–1.59)	1.19 (0.80–1.77)	1.29 (0.92–1.80)
BMI in kg/m² (per 1)	0.97 (0.93–1.02)	0.99 (0.95–1.04)	1.07 (0.97–1.17)	0.97 (0.90–1.03)
Tumour size
Under 25 mm	1.00	1.00	1.00	1.00
25–50 mm	1.00 (0.62–1.60)	1.32 (0.72–2.42)	1.54 (0.55–4.34)	0.75 (0.33–1.71)
More than 50 mm	1.58 (0.91–2.72)	2.66 (1.44–4.89)	2.16 (0.76–6.16)	1.12 (0.49–2.57)
Size (per 10 mm)	1.04 (0.97–1.13)	1.08 (1.02–1.15)	1.05 (0.94–1.17)	1.03 (0.95–1.10)
Mode of discovery
Synchronous	2.17 (1.47–3.20)	1.33 (0.84–2.10)	0.98 (0.37–2.58)	3.83 (1.53–9.55)
Metachronous	1.00	1.00	1.00	1.00
Extra-adrenal metastases at time of surgery
No	1.00	1.00	1.00	1.00
Yes	1.21 (0.81–1.83)	1.79 (1.07–3.01)	1.41 (0.66–3.00)	1.71 (0.96–3.04)
Surgical approach
Laparoscopic	1.00	1.00	1.00	1.00
Open	2.07 (1.38–3.09)	1.27 (0.69–2.36)	1.11 (0.53–2.31)	2.00 (1.12–3.58)
Radicality
R0 resection	1.00	1.00	1.00	1.00
R1 resection	1.79 (1.24–2.60)	2.35 (1.51–3.65)	1.90 (0.92–3.90)	0.83 (0.46–1.50)
R2 resection	3.02 (0.93–9.74)	2.47 (0.98–6.25)	4.58 (0.99–21.17)	3.60 (1.07–12.10)

Table 3

Open in new tab

Prognostic factors by primary cancer

	Renal cancer crude HR (95% c.i.)	Lung cancer crude HR (95% c.i.)	Colorectal cancer crude HR (95% c.i.)	Other cancer crude HR (95% c.i.)
Sex
Female	1.28 (0.88–1.85)	0.95 (0.62–1.46)	0.92 (0.40–2.14)	0.77 (0.42–1.40)
Male	1.00	1.00	1.00	1.00
Age (per 10 years)	1.16 (0.96–1.40)	0.73 (0.55–0.98)	1.52 (0.95–2.41)	1.05 (0.78–1.42)
Age at surgery
Under 60 years	1.00	1.00	1.00	1.00
60–70 years	1.10 (0.71–1.72)	0.66 (0.41–1.07)	1.45 (0.48–4.32)	0.72 (0.36–1.43)
More than 70 years	1.26 (0.79–2.01)	0.50 (0.27–0.93)	3.16 (1.07–9.30)	1.55 (0.78–3.08)
CCI (per 1)	1.12 (0.98–1.28)	1.25 (0.99–1.59)	1.19 (0.80–1.77)	1.29 (0.92–1.80)
BMI in kg/m² (per 1)	0.97 (0.93–1.02)	0.99 (0.95–1.04)	1.07 (0.97–1.17)	0.97 (0.90–1.03)
Tumour size
Under 25 mm	1.00	1.00	1.00	1.00
25–50 mm	1.00 (0.62–1.60)	1.32 (0.72–2.42)	1.54 (0.55–4.34)	0.75 (0.33–1.71)
More than 50 mm	1.58 (0.91–2.72)	2.66 (1.44–4.89)	2.16 (0.76–6.16)	1.12 (0.49–2.57)
Size (per 10 mm)	1.04 (0.97–1.13)	1.08 (1.02–1.15)	1.05 (0.94–1.17)	1.03 (0.95–1.10)
Mode of discovery
Synchronous	2.17 (1.47–3.20)	1.33 (0.84–2.10)	0.98 (0.37–2.58)	3.83 (1.53–9.55)
Metachronous	1.00	1.00	1.00	1.00
Extra-adrenal metastases at time of surgery
No	1.00	1.00	1.00	1.00
Yes	1.21 (0.81–1.83)	1.79 (1.07–3.01)	1.41 (0.66–3.00)	1.71 (0.96–3.04)
Surgical approach
Laparoscopic	1.00	1.00	1.00	1.00
Open	2.07 (1.38–3.09)	1.27 (0.69–2.36)	1.11 (0.53–2.31)	2.00 (1.12–3.58)
Radicality
R0 resection	1.00	1.00	1.00	1.00
R1 resection	1.79 (1.24–2.60)	2.35 (1.51–3.65)	1.90 (0.92–3.90)	0.83 (0.46–1.50)
R2 resection	3.02 (0.93–9.74)	2.47 (0.98–6.25)	4.58 (0.99–21.17)	3.60 (1.07–12.10)

	Renal cancer crude HR (95% c.i.)	Lung cancer crude HR (95% c.i.)	Colorectal cancer crude HR (95% c.i.)	Other cancer crude HR (95% c.i.)
Sex
Female	1.28 (0.88–1.85)	0.95 (0.62–1.46)	0.92 (0.40–2.14)	0.77 (0.42–1.40)
Male	1.00	1.00	1.00	1.00
Age (per 10 years)	1.16 (0.96–1.40)	0.73 (0.55–0.98)	1.52 (0.95–2.41)	1.05 (0.78–1.42)
Age at surgery
Under 60 years	1.00	1.00	1.00	1.00
60–70 years	1.10 (0.71–1.72)	0.66 (0.41–1.07)	1.45 (0.48–4.32)	0.72 (0.36–1.43)
More than 70 years	1.26 (0.79–2.01)	0.50 (0.27–0.93)	3.16 (1.07–9.30)	1.55 (0.78–3.08)
CCI (per 1)	1.12 (0.98–1.28)	1.25 (0.99–1.59)	1.19 (0.80–1.77)	1.29 (0.92–1.80)
BMI in kg/m² (per 1)	0.97 (0.93–1.02)	0.99 (0.95–1.04)	1.07 (0.97–1.17)	0.97 (0.90–1.03)
Tumour size
Under 25 mm	1.00	1.00	1.00	1.00
25–50 mm	1.00 (0.62–1.60)	1.32 (0.72–2.42)	1.54 (0.55–4.34)	0.75 (0.33–1.71)
More than 50 mm	1.58 (0.91–2.72)	2.66 (1.44–4.89)	2.16 (0.76–6.16)	1.12 (0.49–2.57)
Size (per 10 mm)	1.04 (0.97–1.13)	1.08 (1.02–1.15)	1.05 (0.94–1.17)	1.03 (0.95–1.10)
Mode of discovery
Synchronous	2.17 (1.47–3.20)	1.33 (0.84–2.10)	0.98 (0.37–2.58)	3.83 (1.53–9.55)
Metachronous	1.00	1.00	1.00	1.00
Extra-adrenal metastases at time of surgery
No	1.00	1.00	1.00	1.00
Yes	1.21 (0.81–1.83)	1.79 (1.07–3.01)	1.41 (0.66–3.00)	1.71 (0.96–3.04)
Surgical approach
Laparoscopic	1.00	1.00	1.00	1.00
Open	2.07 (1.38–3.09)	1.27 (0.69–2.36)	1.11 (0.53–2.31)	2.00 (1.12–3.58)
Radicality
R0 resection	1.00	1.00	1.00	1.00
R1 resection	1.79 (1.24–2.60)	2.35 (1.51–3.65)	1.90 (0.92–3.90)	0.83 (0.46–1.50)
R2 resection	3.02 (0.93–9.74)	2.47 (0.98–6.25)	4.58 (0.99–21.17)	3.60 (1.07–12.10)

i.q.r., interquartile range; CCI, Charlson co-morbidity index; HR, hazard ratio. Cox proportional regression analysis was used for overall survival after adrenal metastasectomy for each primary cancer.

This Feature Is Available To Subscribers Only